Drugs / NB003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04936178 | Aug 2021 → Aug 2025 | neoplasm | Ningbo Newbay Technology Development Co., Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07379047 | May 2026 → Aug 2028 expected | gastrointestinal stromal tumor | Ningbo Newbay Technology Development Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NB003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07379047 ↗ |
| Route | Oral | “orally twice daily” NCT04936178 ↗ |